Agendia Appoints Dr. M. William Audeh to Chief Medical Officer
IRVINE, CA and AMSTERDAM – Agendia, Inc., a world leader Read More
Agendia’s MammaPrint First and Only Genomic Assay to Receive Level 1A Clinical Utility Evidence for Chemotherapy Benefit in Early Breast Cancer Patients
Clinical high-risk patients with a low-risk MammaPrint® result, including 48 Read More
Agendia to Highlight New MammaPrint Data at the 2016 European Breast Cancer Conference as a Prelude to Upcoming MINDACT Trial Findings
Company will also host a lunch symposium on genomic assays Read More
Agendia Statement in Response to Recent ASCO Guidelines on Biomarker Assay Use in Adjuvant Breast Cancer Care
Agendia is disappointed with the recent update to the American Read More
Agendia and Partners Receive $6.8 million from European Commission to Study Targeted Therapies for Colorectal Cancer
IRVINE, CA and AMSTERDAM, THE NETHERLANDS – Agendia, Inc. and Read More
Agendia’s MammaPrint and BluePrint Breast Cancer Tests to Be Highlighted at San Antonio Symposium
Satellite Symposium and Dinner Presentation Will Offer Latest Insights on Genomic Read More
Agendia Highlights Study Showing MammaPrint/BluePrint Tests Predict Response to Current Breast Cancer Chemotherapy and Targeted Therapy Regimens
Researchers Present Data at Breast Cancer Symposium Showing MammaPrint/BluePrint Can Identify Read More
Agendia Board of Directors Appoints Mark R. Straley as New CEO
IRVINE, CA and AMSTERDAM – Agendia, Inc., a world leader Read More
NCCN Breast Cancer Guidelines Acknowledge MammaPrint’s Ability to Predict Prognosis
Respected Panel Cites RASTER, the Only Published Prospective Outcome Data Read More
